( NASDAQ-NMS:JAZZ )

News from Jazz Pharmaceuticals plc A wide array of domestic and global news stories on topics including politics, business, technology, religion, sports, entertainment, science, health and lifestyle.

Latest News from Jazz Pharmaceuticals plc

11 Sep, 2018, 21:05 BST Jazz Pharmaceuticals Announces an Informational Webcast for Investors Related to Vyxeos EU Launch

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast to provide investors with an overview of the AML...


29 Aug, 2018, 21:05 BST Jazz Pharmaceuticals Announces Participation in Two Upcoming Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor...


27 Aug, 2018, 07:00 BST Vyxeos® Receives Marketing Authorisation in the European Union for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission approved Vyxeos® 44 mg/100 mg powder for concentrate for...


07 Aug, 2018, 21:05 BST Jazz Pharmaceuticals Announces Second Quarter 2018 Financial Results

GAAP Diluted EPS of $1.50; Adjusted Diluted EPS of $3.49 Reflects Growth of 36% Total Revenues of $500 Million, an Increase of 27% Xyrem Product...


06 Aug, 2018, 21:15 BST Jazz Pharmaceuticals and MD Anderson Cancer Center Collaborate to Evaluate Potential Treatment Options for Hematologic Malignancies

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year collaboration agreement...


03 Aug, 2018, 13:00 BST CMS Grants New Technology Add-On Payment to Vyxeos® (daunorubicin and cytarabine) Liposome for Injection

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the United States Centers for Medicare and Medicaid Services (CMS) granted approval...


24 Jul, 2018, 21:05 BST Jazz Pharmaceuticals to Report 2018 Second Quarter Financial Results on August 7, 2018

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2018 second quarter financial results on Tuesday, August 7, 2018,...


19 Jul, 2018, 21:51 BST Journal of Clinical Oncology publishes pivotal Phase 3 data for Jazz Pharmaceuticals' Vyxeos® (daunorubicin and cytarabine) Liposome for Injection

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that data from the pivotal Phase 3 study of Vyxeos® (daunorubicin and cytarabine) liposome...


29 Jun, 2018, 21:05 BST Jazz Pharmaceuticals Enters Into Agreement with TerSera Therapeutics LLC for Prialt

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a definitive agreement to sell its rights related to Prialt® (ziconotide) intrathecal...


29 Jun, 2018, 13:15 BST Vyxeos™ Receives Positive CHMP Opinion for Treatment of Certain Types of High-Risk Acute Myeloid Leukaemia

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP)...


27 Jun, 2018, 21:15 BST Jazz Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review its...


06 Jun, 2018, 21:05 BST Jazz Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Goldman Sachs 39th...


03 Jun, 2018, 22:00 BST Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data for Xyrem® (sodium oxybate) in Pediatric Patients with Narcolepsy with Cataplexy

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Xyrem® (sodium oxybate) oral solution, CIII, demonstrated long-term efficacy for up to...


03 Jun, 2018, 22:00 BST Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sleepiness in Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its investigational treatment solriamfetol demonstrated long-term maintenance of...


31 May, 2018, 13:30 BST New Survey Highlights Lack of Awareness of Neurologic Effects Related to Excessive Sleepiness in Patients with Obstructive Sleep Apnea

Survey findings show that while pulmonologists, neurologists and psychiatrists are aware of the negative effects of Excessive Sleepiness (ES) on...


24 May, 2018, 21:05 BST Jazz Pharmaceuticals Announces Webcast Discussion of Data to be Presented at APSS

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast to discuss data to be presented on solriamfetol...


10 May, 2018, 13:30 BST Jazz Pharmaceuticals to Highlight Breadth of Research in Narcolepsy and Excessive Sleepiness in Obstructive Sleep Apnea at SLEEP 2018 Annual Meeting

Twenty abstracts including eight oral presentations to showcase Jazz's breadth and depth of sleep medicine innovation Jazz Pharmaceuticals...


09 May, 2018, 21:05 BST Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at three upcoming investor...


08 May, 2018, 21:05 BST Jazz Pharmaceuticals Announces First Quarter 2018 Financial Results

Total Revenues Increased 18% to $445 Million Supplemental New Drug Application Submitted to FDA for Xyrem in the Treatment of Pediatric Narcolepsy...


01 May, 2018, 13:30 BST Jazz Pharmaceuticals Submits Supplemental New Drug Application for Xyrem® (sodium oxybate) to Treat Cataplexy and Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it has filed a supplemental new drug application (sNDA) with the U.S. Food and Drug...


24 Apr, 2018, 21:05 BST Jazz Pharmaceuticals to Report 2018 First Quarter Financial Results on May 8, 2018

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2018 first quarter financial results on Tuesday, May 8, 2018, after...


06 Mar, 2018, 21:05 GMT Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor...


02 Mar, 2018, 13:30 GMT Jazz Pharmaceuticals Announces FDA Acceptance of NDA for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with standard...


27 Feb, 2018, 21:05 GMT Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results

Total Revenues of $1.6 Billion in 2017 GAAP EPS of $7.96 Per Share in 2017 Adjusted Non-GAAP EPS of $11.04 Per Share in 2017 Solriamfetol New...


23 Feb, 2018, 13:30 GMT Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 2 clinical trial evaluating the...